Fig. 4From: Stem cell library screen identified ruxolitinib as regulator of osteoblastic differentiation of human skeletal stem cellsRuxolitinib affects multiple pathways during osteoblastic differentiation of hBMSCs. a Heat map analysis and unsupervised hierarchical clustering performed on differentially expressed genes during osteoblast differentiation of ruxolitinib-treated compared to DMSO-treated control hBMSCs. b Pie chart illustrating the distribution of selected enriched pathway categories for the downregulated genes identified in osteoblast differentiated ruxolitinib-treated hBMSCs compared to DMSO-treated control cells. c Validation of a selected panel of downregulated genes during osteoblastic differentiation of ruxolitinib-treated hBMSCs compared to DMSO-treated control cells using qRT-PCR. Gene expression was normalized to β-actin. Data are presented as mean fold change ± SEM (n = 6) from two independent experiments; *P < 0.05; ***P < 0.0005Back to article page